ESKAPE Pathogens: Bad Bugs with No Drugs- A Study in Tertiary Care Hospital

Download Article

DOI: 10.21522/TIJMD.2013.04.02.Art001

Authors : Mowna Karthick


ESKAPE pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species are currently the cause of majority of hospital infections globally and they also effectively “escape” the effects of antibacterial drugs. The UNSTOPPABLE SUCCESS of these SUPERBUGS will lead to UNWINNABLE WAR. It has been suggested that resistance by these organisms are due to mutations, modification of LPS. As the crisis of antibiotic resistance continues to grow, the latest IDSA(Infectious disease society of America) "Bad Bugs, No Drugs" report examines the trickle of new antibiotics in the research and development (R&D) pipeline and proposes steps to tackle the shortage. The aim of the study was to characterize the antimicrobial resistance in ESKAPE pathogens isolated from 430 culture positive clinical sample like urine, pus, blood, wound swab and sputum,. Antibiotic resistance was determined by VITEK 2 and manual Kirby Bauer method. MIC was determined by VITEK 2 and E Test according to Clinical and Laboratory Standards Institute (CLSI). ESKAPE pathogens account for 63%. Except for S. aureus multiple drug resistance (MDR) index of ESKAPE pathogens revealed an increasing trend. The statistical analysis was done for hospital acquired and community acquired MDR infections. Extended spectrum betalactamase (ESBL), Klebsiellaspp., carbapenem resistant, A. baumannii and P. aeruginosa were identified mainly in hospital acquired than in community acquired infections. In conclusion, ESKAPE pathogens are commonly identified in alarming frequency and knowledge of antimicrobial resistance will be aided for empirical treatment.

Keywords: Multi drug Resistant, ESKAPE pathogens, Infections, antibiotics.


[1]. Abdul Ghafur1, Vidyalakshmi PR1, A Murali. Emergence of Pan-drug resistance amongst gram negative bacteria! The First case series from India, Journal of Microbiology and Infectious Diseases / (2014); 4 (3): 86-91 JMID doi: 10.5799/ahinjs

[2]. Anima Poudyal, Benjamin P. Howden In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumonia new Journal of Antimicrobial Chemotherapy (2008) 62, 1311–1318 doi:10.1093/jac/dkn425 Advance Access publication 15 October (2008)

[3]. Azza Elemam, Joseph Rahimian, and William Mandell. Infection with Panresistant Klebsiella pneumoniae: A Report of 2 Cases and a Brief Review of the Literature Clin Infect Dis. (2009) 49 (2): 271-274. doi: 10.1086/600042

[4]. Brooke A. Napier,a, b Eileen M. Burd, c, f Sarah W. Satola, c, d, e Stephanie M. Cagle, c, e Susan M. Ray,c, e, i Patrick McGann, g Jan Pohl, h Emil P. Lesho, g David S. Weiss a, b, c Clinical Use of Colistin Induces Cross-Resistance to Host Antimicrobials in Acinetobacter baumannii (2013) 4 (3).

[5]. Chua SL, Yam JKH, Sze KS, Yang L (2016).”Selective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms". Nat Commun. 7:10750. doi:10.1038/ncomms10750. PMID 26892159.

[6]. Ching Jou Lim, Allen C. Cheng Prevalence of multidrug resistant organisms and risk factors for carriage in long-term care facilities: a nested case–control study. Antimicrob Chemother(2014); 69: 1972–1980 doi:10.1093/jac/dku077 Advance Access publication 7 April 2014

[7]. Rafael López-Rojas,a,c Michael J. McConnell,a,c Manuel Enrique Jiménez-Mejías, Colistin Resistance in a Clinical Acinetobacter baumannii Strain Appearing after Colistin Treatment: Effect on Virulence and Bacterial Fitness. Antimicrobial agents chemother (2013) sep; 57 (9). Federico Perez, Andrea M. Hujer, Kristine M. Hujer, Brooke K. Decker, Philip N. Rather, and Robert A. Bonomo. Global Challenge of Multidrug-Resistant Acinetobacter baumannii ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. (2007), p. 3471–3484 Vol. 51, No. 10 0066-4804/07/$08.000 doi:10.1128/AAC.01464-06 Copyright © 2007, American Society for Microbiology.

[8]. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2009);52:813-21.

[9]. National Nosocomial Infections Surveillance System Report, data summary from January 1992 through June (2004) issued October 2004. Am J Infect Control 2004;32:470-85.

[10]. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis (2009);197:1079-81.

[11]. Spellberg B, Guidos R, Gilbert D The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2009);46:155-64.